Peer-influenced content. Sources you trust. No registration required. This is HCN.
Oncology News Central (ONC)
Interim results from J&J’s Phase I study of JNJ-6420 highlight both promising efficacy in prostate cancer treatment and serious safety concerns, with 60% of patients experiencing severe adverse events.
Oncology, Medical June 3rd 2024
Radiopharmaceuticals represent a burgeoning frontier in cancer treatment, offering targeted therapies that minimize collateral damage to healthy tissues.
Oncology, Medical May 13th 2024
CME 
JOBS 
OUTBREAKS 
PEER-TO-PEER 
QUIZZES & QUESTIONS 
MEDTECH